Palatin Technologies, Inc. (PTNT)
OTCMKTS · Delayed Price · Currency is USD
7.27
-0.63 (-7.97%)
At close: Oct 7, 2025
Palatin Technologies Employees
Palatin Technologies had 29 employees as of June 30, 2025. The number of employees decreased by 1 or -3.33% compared to the previous year.
Employees
29
Change (1Y)
-1
Growth (1Y)
-3.33%
Revenue / Employee
n/a
Profits / Employee
-$596,805
Market Cap
7.98M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 29 | -1 | -3.33% |
| Jun 30, 2024 | 30 | -4 | -11.76% |
| Jun 30, 2023 | 34 | 1 | 3.03% |
| Jun 30, 2022 | 33 | 7 | 26.92% |
| Jun 30, 2021 | 26 | 6 | 30.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Silence Therapeutics | 116 |
| Jushi Holdings | 1,234 |
| Nuo Therapeutics | 9 |
Palatin Technologies News
- 15 days ago - Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim - PRNewsWire
- 7 weeks ago - Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases - GlobeNewsWire
- 2 months ago - Palatin Announces 1-for-50 Reverse Stock Split - PRNewsWire
- 3 months ago - Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity - PRNewsWire
- 5 months ago - Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update - PRNewsWire
- 5 months ago - Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 - PRNewsWire
- 5 months ago - Palatin Technologies Announces Closing of Reduced Public Offering - PRNewsWire